Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "Phase 3 RUBY Trial - Dostarlimab + Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer - Analysis of PFS & OS Outcomes by Molecular Classification"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Mansoor Raza Mirza
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Mansoor Raza Mirza
Login to view comments.
Click here to Login
Gynecologic